RAMOT at Tel Aviv University Ltd.

hOMCs for the treatment of neurological diseases

Posted by RAMOT at Tel Aviv University Ltd.Responsive · Innovative Products and Technologies · Israel

Summary of the technology

Sandu Pitaru has IP related to human oral mucosal stem cells. He will collaborate with Dani Offen to study the application of these cells in neurological disease.


Project ID : 2-2011-173

Technology

A novel pluripotent stem cell population, termed hOMSCs, has been isolated from adult human oral mucosa. The hOMSC population expresses markers of pluripotent embryonic stem cells and of multipotent mesenchymal stem cell markers. hOMSCs form the majority of primary oral mucosa-derived populations grown in culture. Thus, their clinical use does not require cumbersome and expensive isolation/purification steps. A biopsy of a 4-5 mm2 from the oral mucosa is sufficient for generating 109 hOMSCs in a few weeks. Biopsy harvest is extremely simple, time-and cost-efficient, causes minimal morbidity to the patient and can be repeated unlimitedly. Furthermore, the frequency and "stemness" of hOMSCs is unaffected by the age of the patient.

Both in vitro and in vivo studies using these cells have demonstrated their efficacy and safety in different indications.

Mesodermal lineages (vascular tissue; bone; cartilage; muscle); Ectodermal lineages (Neurons; glia cells); Endoderm (Definitive endoderm – future development to pancreatic and hepatic lineages)

Data–to-date

  • Differentiated hOMSC show astrocyte-like phenotype
  • Differentiated hOMSC : a vehicle for NTF (or dopamine) delivery
  • hOMSC differentiate into ligament fibroblasts capable of forming ligamentous structures that will strengthen the post-MI scared myocardium and thereby prevent the myocardial remodeling that leads to terminal ischemic heart failure

Potential Application

  • Heart Diseases
  • Cartilage and bone diseases or trauma
  • Diabetes
  • Neurodegenerative diseases
  • Neural injuries
  • Regenerative medicine
  • Inflammatory diseases

Advantages

  • Pluripotent autogenous adult stem cell source
  • Stemness is not affected by the patient age
  • Simple, cost-effective and unlimited source of adult pluripotent stem cells
  • Stemness is not affected by cryopreservation and number of passages


Project manager

Adi Elkeles
BD Manager

Project researchers

Sandu Pitaru
T.A.U Tel Aviv University, Medicine-Sackler Faculty
Dental school

Daniel Offen
T.A.U Tel Aviv University, Medicine-Sackler Faculty
Felsenstein Medical Res Center-Beilinson

Related keywords

  • Medicine, Human Health
  • Medical Technology / Biomedical Engineering
  • Biology / Biotechnology
  • Cellular and Molecular Biology Technology
  • Microbiology Technology
  • Bioinformatics Technology
  • Micro- and Nanotechnology related to Biological sciences
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Bioinformatics Market
  • Therapeutic
  • Clinical Medicine
  • Life Sciences and Biotechnology
  • Life Sciences and Biotechnology
  • Stem Cells
  • Cell therapy

About RAMOT at Tel Aviv University Ltd.

Technology Transfer Office from Israel

Ramot is Tel Aviv University's (TAU) technology transfer company and its liaison to industry, bringing promising scientific discoveries made at

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.